Immunochromatographic test paper for rapidly detecting bladder cancer by utilizing anti-nuclear matrix protein 22 antibodies and preparation method of test paper

Abstract

The invention belongs to the technical field of in vitro diagnosis and particularly relates to immunochromatographic test paper for rapidly detecting bladder cancer by utilizing anti-nuclear matrix protein 22 antibodies. The immunochromatographic test paper comprises a sample pad 1, a binding pad 2, a nitrocellulose membrane 3, water-absorbing paper 4 and a bottom board 5, wherein the nitrocellulose membrane 3 is arranged at the middle part of the bottom board 5; one end of the nitrocellulose membrane 3 is provided with the binding pad 2 and the sample pad 1 in sequence along the bottom board, and the other end of the nitrocellulose membrane 3 is provided with the water-absorbing paper 4 along the bottom board; the nitrocellulose membrane 3 comprises a detection area coated with the anti-nuclear matrix protein 22 antibodies and a quality control area coated with anti-IgG antibodies; a detection line (T) is arranged in the detection area and a quality control line (C) is arranged in the quality control line; and the binding pad 2 is coated with the colloidal-gold-labeled anti-nuclear matrix protein 22 antibodies or latex-labeled anti-nuclear matrix protein 22 antibodies or colloidal-selenium-labeled anti-nuclear matrix protein 22 antibodies. The immunochromatographic test paper has the characteristics of simplicity, convenience and no invasion in use and can be applied to clinical auxiliary diagnosis and detection of conditions of bladder cancer.

Description

technical field [0001] The invention belongs to the technical field of in vitro diagnosis, in particular to an immunochromatographic test paper for rapidly detecting bladder cancer by using an anti-nuclear matrix protein 22 (NMP22) antibody. [0002] Background technique [0003] Bladder tumors are the most common tumors of the urinary system, and more than 90% are transitional cell carcinomas. Transitional cell carcinoma of the bladder is the most common malignant tumor of the urinary system, mostly occurring between the ages of 50 and 70. More than 80% of them are superficial tumors, and 10%-20% develop into invasive bladder cancer. This disease has a high mortality rate, and early detection and diagnosis play an important role in treatment and prognosis. Data show that the 5-year survival rate of patients diagnosed in the early stage of the disease is greater than 90%, while the 5-year survival rate of patients diagnosed in the late stage is only about 15%-30%. At pres...

AI Technical Summary

Problems solved by technology

At present, the diagnosis and postoperative review of bladder cancer mainly rely on cystoscopy and urine cytology examination. Although the former is accurate, it is an invasive examination, which is complicated, time-consuming, laborious, expensive, and brings great pain to the patient. Many patients are resistant to this method, and it is difficult to find carcinoma in situ or flat carcinoma; urine cytology is non-invasive and has good specificity, but low sensitivity. It is sensitive to tumors with lower stages and better differentiation. Only 30% or lower, and it is greatly affected by the subjective factors of the diagnostician

The limitations of cystoscopy and urine cytology limit the application of bladder cancer diagnosis, so it is of great significance to find a simple, non-invasive and early diagnosis of bladder cancer experimental method

Images